LigoCyte Pharmaceuticals has forged a deal to co-develop anti-inflammatory drugs with Biogen Idec. Researchers from both companies will be developing drugs that target CD103, a unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs. Those diseases can include respiratory, gastrointestinal, and autoimmune disorders. LigoCyte stands to earn a schedule of milestones for successful programs and retains co-development and co-promotion rights on new drugs as well.
- check out the release
- here's the report from the Triangle Business Journal
Related Articles:
Biogen Idec's CEO nets bonus despite bad year. Report
Biogen Idec considering sale of cancer drug. Report